Cell 31 (6), 722733 (2014)
Body composition imaging from the same trial showed that approximately three-quarters of the total weight reduction came from fat tissue, with a smaller share coming from lean mass.[1] That fat-to-lean ratio is more favorable than dieting alone tends to produce and is similar to or slightly better than the ratios reported for semaglutide (the drug in Ozempic and Wegovy) and tirzepatide (the drug in Mounjaro and Zepbound).[6][7] A Trillion Dollar Class of Drugs For perspective on the scale, Vineeta Agarwala, a general partner at the venture capital firm Andreessen Horowitz (a16z) who leads the firm's Bio and Health investments, recently noted that tirzepatide (the existing Mounjaro and Zepbound molecule) is on pace for roughly $45 billion in global sales in 2026 , against about $230 billion in global iPhone sales the same year.[11] With retatrutide and other next-generation peptides building on top of that base, the GLP-1 and multi-agonist category is on a credible path to becoming a trillion-dollar drug class over the coming decade-plus, a scale only a handful of pharmaceutical categories have ever reached
[1] [4] Symptoms of hypoglycaemia include trembling, sweating, confusion, palpitations, and in severe cases, loss of consciousness
Wegovy is manufactured by Novo Nordisk, which is one of the largest producers of health products in the world
